SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-23-031085
Filing Date
2023-11-09
Accepted
2023-11-09 09:00:40
Documents
13
Period of Report
2023-11-09
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K atos20231106_8k.htm   iXBRL 8-K 22183
  Complete submission text file 0001437749-23-031085.txt   153486

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA atos-20231109.xsd EX-101.SCH 3410
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE atos-20231109_def.xml EX-101.DEF 11425
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE atos-20231109_lab.xml EX-101.LAB 15311
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atos-20231109_pre.xml EX-101.PRE 11585
7 EXTRACTED XBRL INSTANCE DOCUMENT atos20231106_8k_htm.xml XML 2549
Mailing Address 107 SPRING STREET SEATTLE WA 98104
Business Address 107 SPRING STREET SEATTLE WA 98104 206.588.0256
ATOSSA THERAPEUTICS, INC. (Filer) CIK: 0001488039 (see all company filings)

IRS No.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35610 | Film No.: 231390283
SIC: 2834 Pharmaceutical Preparations